^Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, et al. (June 2006). "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans". Drug Metabolism and Disposition. 34 (6): 961–70.
doi:
10.1124/dmd.105.007500.
PMID16540589.
S2CID25629874.
^Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM (May 2001). "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat". Journal of Hypertension. 19 (5): 941–6.
doi:
10.1097/00004872-200105000-00015.
PMID11393678.
S2CID9162678.
^Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, et al. (June 2006). "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans". Drug Metabolism and Disposition. 34 (6): 961–70.
doi:
10.1124/dmd.105.007500.
PMID16540589.
S2CID25629874.
^Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM (May 2001). "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat". Journal of Hypertension. 19 (5): 941–6.
doi:
10.1097/00004872-200105000-00015.
PMID11393678.
S2CID9162678.